they're not ignoring the survival data, they're asking for different data - ie. the data the proves batch potency consistency so that they know that the 40 odd percent that didn't survive at 2 years sadly passed away because this is a nasty, nasty beast rather than because they got a weaker batch than the ones that survived.
in fairness they've been pretty consistent with that request all along.
Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-32
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.065(4.66%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| $1.41 | $1.50 | $1.40 | $5.699M | 3.943M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 122380 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 11015 | 2 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |